Presence of glucagon-(1-21)-Like immunoreactive substance in the dog small intestinal mucosa.
By using an antiserum (K291) specifically directed to the C-terminal of glucagon-(1-21)-peptide, we demonstrated the presence of glucagon-(1-21)-like immunoreactivity (G21-IR) in the dog intestine. G21-IR was found to be widely distributed throughout the small intestine and colon in parallel with the distribution of glucagon-like immunoreactivity (GLI), measured by N-terminal glucagon antiserum (OAL196). The subsequent analyses by gel filtration and three HPLC columns (reverse phase, ion exchange and further reverse phase columns) showed that G21-IR consisted of three main peaks, and the smallest molecular form of G21-IR is identical to glucagon-(1-21)-peptide.
Itoh
H
H
Second Department of Internal Medicine, Osaka University Medical School, Japan.
Namba
M
M
Watanabe
N
N
Ohara
T
T
Matsuyama
T
T
Komatsu
R
R
Shinomura
Y
Y
Kono
N
N
Tarui
S
S
D000595:Amino Acid Sequence; D000818:Animals; D002850:Chromatography, Gel; D002851:Chromatography, High Pressure Liquid; D004285:Dogs; D005934:Glucagon / Q000032:analysis*; D004763:Glucagon-Like Peptides; D007413:Intestinal Mucosa / Q000032:analysis*; D007421:Intestine, Small / Q000032:analysis*; D008969:Molecular Sequence Data; D010446:Peptide Fragments / Q000032:analysis*; D010455:Peptides / Q000032:analysis; D011863:Radioimmunoassay; D014018:Tissue Distribution
D010446:Peptide Fragments; D010455:Peptides; C043386:glucagon (1-21); D004763:Glucagon-Like Peptides; C015236:glucagon-like-immunoreactivity; D005934:Glucagon